6262-34-6

Usage

Uses

Used in Medicinal Chemistry:
2-(naphthalen-1-ylamino)acetic acid is used as a building block in the development of new drugs and pharmaceuticals for its potential medicinal properties.
Used in Organic Synthesis:
2-(naphthalen-1-ylamino)acetic acid is used as a building block in organic synthesis for its ability to form various chemical compounds.
Used in Chemical Research:
2-(naphthalen-1-ylamino)acetic acid is used in chemical research to study its properties and potential applications.
Used in Industrial Applications:
2-(naphthalen-1-ylamino)acetic acid is used in the production of dyes and other organic chemicals for its chemical properties.
Used in Pharmaceutical Development:
2-(naphthalen-1-ylamino)acetic acid is used as a building block in the development of new pharmaceuticals for its potential therapeutic effects.

Upstream product

• 134-32-7 1-amino-naphthalene 
• 96-32-2 bromoacetic acid methyl ester 
• 79-11-8 chloroacetic acid 
• 107456-67-7 ethyl (N-naphthalen-1-yl-amino)acetate 
• 598-21-0 2-Bromoacetyl bromide 
• 170919-33-2 methyl 2-(naphthalen-1-ylamino)acetate 
• 123-51-3 i-Amyl alcohol 
• 298-12-4 Glyoxilic acid 

Downstream Products

• 6361-33-7 N-(1-naphthyl)benzylamine 

Relevant academic research and scientific papers

Acyl dipeptides as reversible caspase inhibitors. Part 2: Further optimization

A new structural class of broad spectrum caspase inhibitors was optimized for its activity against caspases 1, 3, 6, 7, and 8. The most potent compound had low nanomolar broad spectrum activity, in particular, single digit nanomolar inhibitory activity ag

Dual fluorescence of naphthylamines in alkaline aqueous solution

Dual fluorescence was observed with N-(1-naphthyl)aminoacetate (1-NAA) in aqueous solution of pH 13.0 in the presence of cationic surfactants, cetyltrimethylammonium bromide (CTAB) and chloride (CTAC), below and after the critical micelle concentration (CMC). Similar dual fluorescence was also found with 1- and 2-naphthylamine (1-NA, 2-NA), N-(2-naphthyl)aminoacetate (2-NAA) and (1-naphthyl)ethylenediamine (1-NEDA), in the presence and absence of the cationic surfactants, but not with N,N-disubstituted 1- and 2-NAs. We concluded that the dual fluorescence was due to the excited-state deprotonation of the amino group in these NAs. The pKa>s of the dual fluorescent NAs were estimated to be around 14 from the dual fluorescence pH titrations. No clear correlation was found for pKa> with the amino substitution and the presence of cationic micelle.

Discovery and evolution of 12N-substituted aloperine derivatives as anti-SARS-CoV-2 agents through targeting late entry stage

So far, there is still no specific drug against COVID-19. Taking compound 1 with anti-EBOV activity as the lead, fifty-four 12N-substituted aloperine derivatives were synthesized and evaluated for the anti-SARS-CoV-2 activities using pseudotyped virus model. Among them, 8a exhibited the most potential effects against both pseudotyped and authentic SARS-CoV-2, as well as SARS-CoV and MERS-CoV, indicating a broad-spectrum anti-coronavirus profile. The mechanism study disclosed that 8a might block a late stage of viral entry, mainly via inhibiting host cathepsin B activity rather than directly targeting cathepsin B protein. Also, 8a could significantly reduce the release of multiple inflammatory cytokines in a time- and dose-dependent manner, such as IL-6, IL-1β, IL-8 and MCP-1, the major contributors to cytokine storm. Therefore, 8a is a promising agent with the advantages of broad-spectrum anti-coronavirus and anti-cytokine effects, thus worthy of further investigation.

Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds

Targeting the protein-protein interaction (PPI) between nuclear factor erythroid 2-related factor 2 (Nrf2) and Kelch-like ECH-associated protein 1 (Keap1) is a potential therapeutic strategy to control diseases involving oxidative stress. Here, six classes of known small-molecule Keap1-Nrf2 PPI inhibitors were dissected into 77 fragments in a fragment-based deconstruction reconstruction (FBDR) study and tested in four orthogonal assays. This gave 17 fragment hits of which six were shown by X-ray crystallography to bind in the Keap1 Kelch binding pocket. Two hits were merged into compound 8 with a 220-380-fold stronger affinity (Ki = 16 μM) relative to the parent fragments. Systematic optimization resulted in several novel analogues with Ki values of 0.04-0.5 μM, binding modes determined by X-ray crystallography, and enhanced microsomal stability. This demonstrates how FBDR can be used to find new fragment hits, elucidate important ligand-protein interactions, and identify new potent inhibitors of the Keap1-Nrf2 PPI.

One-pot synthesis of 1,4-disubstituted pyrazoles from arylglycines via copper-catalyzed sydnone-alkyne cycloaddition reaction

A robust method for constructing 1,4-pyrazoles from arylglycines was developed using the copper-catalyzed sydnone-alkyne cycloaddition reaction. The procedure offers a straightforward and general route to the pyrazole heterocycle through a three-step one-pot procedure.

Soluble Polymer-Supported Synthesis of α-Amino Acid Derivatives

A practical and efficient synthesis of N-substituted α-amino acid derivatives on soluble polymer support is described.

(Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases

This invention is directed to novel (substituted)acyl dipeptidyl ICE/ced-3 family inhibitor compounds. The invention is also directed to pharmaceutical compositions containing these compounds, as well as the use of such compositions in the treatment of pa

β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors

β-Amino-α-hydroxycarboxylic acid derivatives represented by the following formula and salts thereof which are useful as human immunodeficiency virus (HIV) protease inhibitors: The compounds are effective for treating a patient suffering from AIDS and AIDS related diseases.